Belatacept for kidney transplant recipients

Philip Masson, Lorna K. Henderson, Jeremy R. Chapman, Jonathan C. Craig, Angela C. Webster

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


This is the protocol for a review and there is no abstract. The objectives are as follows: The objectives of this review are to: Compare the relative efficacy of belatacept versus any other immunosuppressive co-intervention for preventing acute rejection and maintaining kidney transplant function, and composite kidney transplant and recipient survival. Compare the incidence of several adverse events: Post-transplant lymphoproliferative disorder; other malignancies; IF/TA; infective complications; deterioration in blood pressure, lipid and glycaemic control. Assess any variation in effects by study, intervention and recipient characteristics, including: differences in pre-transplant Epstein-Barr virus status; belatacept dosing regimen; and donor-category (living, standard criteria deceased, or extended criteria deceased).

Original languageEnglish
Article numberCD010699
JournalCochrane Database of Systematic Reviews
Issue number8
Publication statusPublished - 15 Aug 2013


Dive into the research topics of 'Belatacept for kidney transplant recipients'. Together they form a unique fingerprint.

Cite this